Ranbaxy Sues First Databank For Trade Libel Over Acne Drug

Law360, New York (July 18, 2013, 3:16 PM EDT) -- Ranbaxy Laboratories Inc. hit drug information publisher First Databank Inc. with a trade libel suit in Florida federal court Wednesday, saying FDB's database falsely indicates that Ranbaxy's Absorica acne drug can be safely substituted with certain other drugs, causing it more than $15 million in damages. 

The U.S. Food and Drug Administration has classified Absorica as a so-called single-source drug — those that can't be substituted by other drugs — but Ranbaxy says FDB's database is causing pharmacists to fill Absorica prescriptions with other drugs, putting...
To view the full article, register now.




Case Information

Case Title

Ranbaxy Laboratories Inc. v. First Databank, Inc.

Case Number



Florida Middle

Nature of Suit

Assault Libel & Slander


Timothy J. Corrigan

Date Filed

July 17, 2013

Law Firms


Government Agencies

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.